Pipeline versus Tubridge in the treatment of unruptured posterior circulation aneurysms

Jin, Hengwei; Lv, Jian; Meng, Xiangyu; Liu, Xinke; He, Hong; Li, Youxiang

doi:10.1186/s41016-023-00337-0

Cited by 3 publications

(2 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Prior research has shown the effectiveness of TFD in treating aneurysms in the PC [ 30 ]. Our study aimed to further explore treatment using TFDs, representing the first multicenter study to compare TFD with PED, which both are FDs used for treating PC aneurysms.…”

Section: Discussionmentioning

confidence: 99%

Comparison of pipeline embolization device and tubridge flow diverter for posterior circulation aneurysms: A multicentre propensity score matched study

Liang,

Tong,

Xue

et al. 2024

Heliyon

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Comparison of pipeline embolization device and tubridge flow diverter for posterior circulation aneurysms: A multicentre propensity score matched study

Liang,

Tong,

Xue

et al. 2024

Heliyon

View full text Add to dashboard Cite

“…17 The Tubridge flow diverter, a native endovascular reconstruction device, has demonstrated excellent efficacy and safety in treating complex aneurysms, with effective occlusion rate and clinical outcome, acceptable adverse events, comparable to other flow diverters. 18,19 We conducted a review of clinical data from five single coiling aneurysms that underwent the procedure. Our results indicate that the devices were successfully implanted without any unfolding failures or adverse events.…”

Section: Safety and Efficacy Of Tubridge Flow Divertermentioning

confidence: 99%

Tubridge flow diverter for the treatment of recurrent cerebral aneurysms

Zhao,

Wang,

Liu

et al. 2024

NeuroAsia

View full text Add to dashboard Cite

Background & Objective: The Tubridge flow diverter is a commonly used device in China for reconstructing the parental artery and occluding complex intracranial aneurysms. However, there is limited experience with the device in treating recurrent intracranial aneurysms. The purpose of this study is to assess the safety and effectiveness of the Tubridge flow diverter in treating recurrent single- coiling aneurysms. Methods: The clinical records of patients with recurrent intracranial aneurysms who were treated with a Tubridge flow diverter were reviewed to show the therapeutic process, occlusion rate, and clinical outcomes associated with this treatment method. Results: Five patients with recurrent aneurysms of the internal carotid artery after singe coiling were included in the study. The recurrent aneurysmal sac had a mean length and width of 8.34/4.30 mm. All five Tubridge flow diverters were implanted without any unfold failure. The last angiographic follow-up showed a complete occlusion rate of 100%. Five branch arteries were covered, and only one branch artery disappeared during follow-up. No cases of cerebral infarction or intracranial hemorrhage were found among the patients. Conclusions: Our initial findings indicate that the Tubridge flow diverter could be a reliable and successful method for treating recurring single-coil aneurysms. We observed that the branch arteries were well-preserved, and no patients experienced cerebral infarction or hemorrhage. However, further research is necessary to establish clear indications and potential complications through a multicenter randomized controlled trial with long-term follow-up.

show abstract

Treatment of intracranial aneurysms using the Tubridge flow diverter

Yuan,

Zhenmei,

Guo

et al. 2024

Postgraduate Medical Journal

View full text Add to dashboard Cite

Objective The Tubridge flow diverter (TFD) was recently developed to treat intracranial aneurysm (IA). In this study, we aimed to assess the safety and efficacy of this novel device. Methods A retrospective cohort of consecutive patients with IA was recruited between June 2017 and February 2022. The studied outcomes were perioperative complications, clinical quality of life, and angiographic IA occlusion. Multivariate logistic regression was performed to explore the potential predictors of perioperative stroke events and IA occlusion. A comprehensive literature review was conducted across five databases for evidence synthesis. Results Among the patients with IA in our cohort, 144 underwent successful TFD implantation. Postoperative stroke was observed in 11 (7.6%) patients, and 130 (90.3%) patients were discharged with modified Rankin scales (mRS) of ≤2. In the last clinical follow-up (mean, 16.9 months), 96.6% of the patients reported a satisfactory quality of life (mRS ≤2). IA occlusion was observed in 84.6% of the patients at the last angiographic follow-up (mean, 10.4 months). Aneurysmal subarachnoid hemorrhage [odds ratio (OR), 6.98; 95% confidence interval (CI), 1.11–43.91] and giant IA (OR, 5.63; 95% CI, 1.15–27.48) were associated with perioperative stroke events. The evidence synthesis found high rates of satisfactory quality of life (rate, 98.8%; 95% CI, 97.1–99.9%) and IA obliteration (rate, 78.5%; 95% CI, 74.0–82.7%) after TFD treatment. The pooled complication rate was 13.6% (95% CI, 10.9–16.5%). Conclusions This study identified a high rate of IA occlusion in patients who received TFD treatment. These patients also reported a satisfactory quality of life. Further studies in larger prospective cohorts with longer follow-up periods are warranted to verify our findings. Key message What is already known on this topic Flow diverter (FD) devices are an optimal tool to modify hemodynamics and treat intracranial aneurysms (IAs). However, the safety and efficacy of a novel self-expanding FD, namely the Tubridge flow diverter (TFD), remain to be fully established owing to the short-term follow-up periods and limited sample size of existing studies. What this study adds In our cohort of patients who received TFD treatment, 96.6% of patients reported satisfactory quality of life at the last clinical follow-up (mean, 16.9 months); and 84.6% of IAs were successfully occluded at the last angiographic follow-up (mean, 10.4 months). Our comprehensive review and evidence synthesis of existing studies on TFD found high rates of satisfactory quality of life (98.8%; 97.1–99.9%) and IA obliteration (78.5%; 74.0–82.7%). How this study might affect research, practice or policy TFD demonstrated satisfactory performance in the treatment of IAs in our cohort. Studies with larger prospective cohorts and longer follow-up periods are warranted to further investigate this promising novel approach.

show abstract

Pipeline versus Tubridge in the treatment of unruptured posterior circulation aneurysms

Cited by 3 publications

References 28 publications

Comparison of pipeline embolization device and tubridge flow diverter for posterior circulation aneurysms: A multicentre propensity score matched study

Comparison of pipeline embolization device and tubridge flow diverter for posterior circulation aneurysms: A multicentre propensity score matched study

Tubridge flow diverter for the treatment of recurrent cerebral aneurysms

Treatment of intracranial aneurysms using the Tubridge flow diverter

Contact Info

Product

Resources

About